Timosaponin BIICAS# 136656-07-0 |
- Officinalisinin I
Catalog No.:BCN2825
CAS No.:57944-18-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 136656-07-0 | SDF | Download SDF |
PubChem ID | 44575945 | Appearance | White powder |
Formula | C45H76O19 | M.Wt | 921.1 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Synonyms | Prototimosaponin A III | ||
Solubility | Soluble in pyridine; sparingly soluble in water | ||
Chemical Name | (2R,3R,4S,5S,6R)-2-[(2S)-4-[(1R,2S,4S,7S,8R,9S,12S,13S,16S,18R)-16-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
SMILES | CC1C2C(CC3C2(CCC4C3CCC5C4(CCC(C5)OC6C(C(C(C(O6)CO)O)O)OC7C(C(C(C(O7)CO)O)O)O)C)C)OC1(CCC(C)COC8C(C(C(C(O8)CO)O)O)O)O | ||
Standard InChIKey | SORUXVRKWOHYEO-FRUGGTEYSA-N | ||
Standard InChI | InChI=1S/C45H76O19/c1-19(18-58-40-37(55)34(52)31(49)27(15-46)60-40)7-12-45(57)20(2)30-26(64-45)14-25-23-6-5-21-13-22(8-10-43(21,3)24(23)9-11-44(25,30)4)59-42-39(36(54)33(51)29(17-48)62-42)63-41-38(56)35(53)32(50)28(16-47)61-41/h19-42,46-57H,5-18H2,1-4H3/t19-,20-,21+,22-,23+,24-,25-,26-,27+,28+,29+,30-,31+,32+,33-,34-,35-,36-,37+,38+,39+,40+,41-,42+,43-,44-,45?/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Timosaponin BII has anti-diabetes, antioxidant, anti-inflammatory, and anti-dementia activities, it can significantly reduce the neurotoxicity induced by beta amyloid peptide 25-35 in primary neurons, the mechanism of which may be related with resisting oxidative damage and regulating the cholinergic system.Timosaponin BII can improve the neurological symptoms of cerebral ischemic rat, reduce infarct size, relieve brain water edema, improve hemorheology, reduce inflammatory injury of cerebral ischemia; it could be used in the preparation of a medicament or product for the prevention and treatment of stroke. |
Targets | Beta Amyloid | BACE | SOD | AChE |
In vitro | Protective effects of timosaponin BII on primary neurons against beta amyloid peptide 25-35.[Reference: WebLink]Chinese Pharmacological Bulletin, 2009, 25(2):244-7.To study the protective effects of Timosaponin BII on primary neurons against beta amyloid peptide 25-35 induced toxicity. |
In vivo | Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice.[Pubmed: 22002851]Planta Med. 2012 Jan;78(1):18-23. doi: 10.1055/s-0031-1280268.In the present study, the anti-diabetic effects of a traditional Chinese medicinal formula extract, TongGuanWan, were investigated in type 2 diabetic animals. Use of Timosaponin BII in the Preparation Of A Medicament or Product for the Prevention and Treatment of Stroke[Reference: WebLink]US20090075912[P]. 2009.The invention disclosed the use of Timosaponin BII in the preparation of a medicament or product for the prevention and treatment of stroke. The experiments prove that Timosaponin BII can improve the neurological symptoms of cerebral ischemic rat, reduce infarct size, relieve brain water edema, improve hemorheology, reduce inflammatory injury of cerebral ischemia. |
Kinase Assay | Timosaponin-BII inhibits the up-regulation of BACE1 induced by ferric chloride in rat retina.[Pubmed: 23082924]BMC Complement Altern Med. 2012 Oct 22;12:189.Our previous studies indicated that oxidative stress up-regulated the expression of β-amyloid precursor protein cleavage enzyme-1 (BACE1) in rat retina. Pharmacological reports have shown Timosaponin BII, a purified extract originating from Chinese medical herb Rhizoma Anemarrhenae, is characterized as an antioxidant. |
Structure Identification | J Asian Nat Prod Res. 2010 Nov;12(11):955-61.Hydrolysis of timosaponin BII by the crude enzyme from Aspergillus niger AS 3.0739.[Pubmed: 21061217 ]Timosaponin BII (1), a steroidal saponin showing potential anti-dementia activity, was regioselectively hydrolyzed into its deglycosyl derivatives by the crude enzyme from Aspergillus niger AS 3.0739. Three biotransformation products, Timosaponin BII-a (2), Timosaponin BII-b (3), and Timosaponin BII-c (4), were purified and their structures were elucidated on the basis of 1D NMR, 2D NMR, FAB-MS, and HR-ESI-MS spectral data. Compounds 2 and 3 are new compounds. |
Timosaponin BII Dilution Calculator
Timosaponin BII Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.0857 mL | 5.4283 mL | 10.8566 mL | 21.7132 mL | 27.1415 mL |
5 mM | 0.2171 mL | 1.0857 mL | 2.1713 mL | 4.3426 mL | 5.4283 mL |
10 mM | 0.1086 mL | 0.5428 mL | 1.0857 mL | 2.1713 mL | 2.7141 mL |
50 mM | 0.0217 mL | 0.1086 mL | 0.2171 mL | 0.4343 mL | 0.5428 mL |
100 mM | 0.0109 mL | 0.0543 mL | 0.1086 mL | 0.2171 mL | 0.2714 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- UK 78282 hydrochloride
Catalog No.:BCC7784
CAS No.:136647-02-4
- Calpain Inhibitor II, ALLM
Catalog No.:BCC1234
CAS No.:136632-32-1
- Senexin A
Catalog No.:BCC7980
CAS No.:1366002-50-7
- Fmoc-Tyr(3-NO2)-OH
Catalog No.:BCC3280
CAS No.:136590-09-5
- Spermine NONOate
Catalog No.:BCC6950
CAS No.:136587-13-8
- Irinotecan HCl Trihydrate
Catalog No.:BCC5091
CAS No.:136572-09-3
- Curdione
Catalog No.:BCN5936
CAS No.:13657-68-6
- Anemarsaponin E
Catalog No.:BCN6290
CAS No.:136565-73-6
- Fmoc-D-Trp-OPfp
Catalog No.:BCC3560
CAS No.:136554-94-4
- BQ-123
Catalog No.:BCC6963
CAS No.:136553-81-6
- Rink Amide Resin
Catalog No.:BCC2570
CAS No.:13653-84-4
- 11β-Hydroxy-2'-methyl-5'βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione
Catalog No.:BCC8435
CAS No.:13649-88-2
- MK-0591
Catalog No.:BCC1753
CAS No.:136668-42-3
- PD 123319 ditrifluoroacetate
Catalog No.:BCC1841
CAS No.:136676-91-0
- 9-Deoxygoniopypyrone
Catalog No.:BCN3931
CAS No.:136685-37-5
- NB-598 hydrochloride
Catalog No.:BCC1787
CAS No.:136719-25-0
- 2-Mercaptoethanesulfonic acid
Catalog No.:BCC1789
CAS No.:3375-50-6
- Minimolide F
Catalog No.:BCN6424
CAS No.:1367351-41-4
- 4,4'-Bismaleimidodiphenylmethane
Catalog No.:BCC8662
CAS No.:13676-54-5
- Gallic aldehyde
Catalog No.:BCN7859
CAS No.:13677-79-7
- Retinyl glucoside
Catalog No.:BCC1891
CAS No.:136778-12-6
- Goniodiol diacetate
Catalog No.:BCN3956
CAS No.:136778-40-0
- Lubiprostone
Catalog No.:BCC4918
CAS No.:136790-76-6
- [Ser25] Protein Kinase C (19-31)
Catalog No.:BCC1022
CAS No.:136795-05-6
Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice.[Pubmed:22002851]
Planta Med. 2012 Jan;78(1):18-23.
In the present study, the anti-diabetic effects of a traditional Chinese medicinal formula extract, TongGuanWan, were investigated in type 2 diabetic animals. It was orally administered to C57BL/KsJ-db/db mice once a day for 4 weeks at the doses of 62, 125, and 250 mg/kg body weight. TongGuanWan significantly lowered the blood glucose and glycosylated haemoglobin levels as well as improved the glucose tolerance in db/db mice. The serum triglyceride levels in the db/db mice were significantly decreased, whereas the high-density lipoprotein cholesterol levels were significantly increased, after treatment with this herbal formula. TongGuanWan also markedly decreased the animals' body weights compared to those of the control db/db group but did not alter food intake. The effects of TongGuanWan were compared to those of the drug rosiglitazone. In addition, five main constituents of TongGuanWan, mangiferin, berberine, cinnamic aldehyde, Timosaponin BII, and timosaponin AIII, were quantified using high performance liquid chromatography coupled with a diode array and an evaporative light scattering detector (HPLC-DAD-ELSD). These results suggest that TongGuanWan may be useful for the treatment of type 2 diabetes.
Timosaponin-BII inhibits the up-regulation of BACE1 induced by ferric chloride in rat retina.[Pubmed:23082924]
BMC Complement Altern Med. 2012 Oct 22;12:189.
UNLABELLED: BACKGROUND: Our previous studies indicated that oxidative stress up-regulated the expression of beta-amyloid precursor protein cleavage enzyme-1 (BACE1) in rat retina. Pharmacological reports have shown Timosaponin-BII, a purified extract originating from Chinese medical herb Rhizoma Anemarrhenae, is characterized as an antioxidant. Our present study aimed to determine whether Timosaponin-BII affected the expression of BACE1, beta-amyloid precursor protein cleavage production of Abeta1-40 and beta-C-terminal fragment (beta-CTF) in rat retina, which were pre-treated with the oxidizing agent (solution of FeCl(3)). RESULTS: Few distinctions of BACE1 distribution were observed among all groups (normal control group, model group, Timosaponin-BII treated and vehicle control groups). Rat retinas in model group and vehicle control group manifested an apparent up-regulation of BACE1 expression. Meanwhile, the level of malonaldehyde (MDA), Abeta1-40 and beta-CTF were increased. However, when comparing with the vehicle control group, the retinas in Timosaponin-BII treated group showed significantly less BACE1 (p<0.05) and accumulated less Abeta1-40 or beta-CTF (p<0.05). It also showed significantly decreased level of MDA (p<0.05) and prolonged partial thromboplastin time (p<0.05). CONCLUSION: Our data suggested that Timosaponin-BII remarkably inhibited the up-regulation of BACE1 and reduced the over-production of beta-CTF and Abeta in rat retina, which was induced by FeCl(3). The mechanism of Timosaponin-BII on BACE1 expression may be related to its antioxidant property.
Hydrolysis of timosaponin BII by the crude enzyme from Aspergillus niger AS 3.0739.[Pubmed:21061217]
J Asian Nat Prod Res. 2010 Nov;12(11):955-61.
Timosaponin BII (1), a steroidal saponin showing potential anti-dementia activity, was regioselectively hydrolyzed into its deglycosyl derivatives by the crude enzyme from Aspergillus niger AS 3.0739. Three biotransformation products, Timosaponin BII-a (2), Timosaponin BII-b (3), and Timosaponin BII-c (4), were purified and their structures were elucidated on the basis of 1D NMR, 2D NMR, FAB-MS, and HR-ESI-MS spectral data. Compounds 2 and 3 are new compounds.